Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; Significant reduction of VEGF by CaMKII inhibitor

BMC Musculoskeletal Disorders

Volumn 11, Issue , 2010, Pages

  Westra, Johanna ^a   Brouwer, Elisabeth ^a   Van Roosmalen, Ingrid A M ^a   Doornbos Van Der Meer, Berber ^a   Van Leeuwen, Miek A ^a   Posthumus, Marcel D ^a   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; RIMACALIB; VASCULOTROPIN; BIOLOGICAL MARKER; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; ENZYME INHIBITOR; HIF1A PROTEIN, HUMAN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CELL LYSATE; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; INFLAMMATION; INTRACELLULAR SIGNALING; MACROPHAGE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUPERNATANT; SYNOVIAL FLUID; ARTHRITIS; CELL CULTURE; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; SYNOVIUM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ARTHRITIS; BIOLOGICAL MARKERS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELL LINE; CELLS, CULTURED; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERLEUKIN-8; MACROPHAGES; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; RNA, MESSENGER; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950452018     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-11-61     Document Type: Article

References (33)

1. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Mulherin D, Fitzgerald O, Bresnihan B, Arthritis Rheum 1996 39 115 124 10.1002/art.1780390116 8546720 (Pubitemid 26036386)
2. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, Meinders AE, Breedveld FC, Arthritis Rheum 1997 40 217 225 10.1002/art.1780400206 9041933 (Pubitemid 27114085)
3. Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseases. Treuhaft PS, MCCarty DJ, Arthritis Rheum 1971 14 475 484 10.1002/art.1780140407 5564921
4. VEGF release is associated with reduced oxygen tensions in experimental inflammatory arthritis. Etherington PJ, Winlove P, Taylor P, Paleolog E, Miotla JM, Clin Exp Rheumatol 2002 20 799 805 12508771 (Pubitemid 35446970)
5. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Semenza GL, Wang GL, Mol Cell Biol 1992 12 5447 5454 1448077
6. Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do! Gaber T, Dziurla R, Tripmacher R, Burmester GR, Buttgereit F, Ann Rheum Dis 2005 64 971 980 10.1136/ard.2004.031641 15800008 (Pubitemid 40909509)
7. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ, Nature 1999 399 271 275 10.1038/20459 10353251 (Pubitemid 29246458)
8. Oxygen sensing by HIF hydroxylases. Schofield CJ, Ratcliffe PJ, Nat Rev Mol Cell Biol 2004 5 343 354 10.1038/nrm1366 15122348 (Pubitemid 38579472)
9. Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. Hellwig-Burgel T, Stiehl DP, Wagner AE, Metzen E, Jelkmann W, J Interferon Cytokine Res 2005 25 297 310 10.1089/jir.2005.25.297 15957953 (Pubitemid 40911381)
10. Cytokines and hormones in the regulation of hypoxia inducible factor-1alpha (HIF-1alpha). Zhou J, Brune B, Cardiovasc Hematol Agents Med Chem 2006 4 189 197 10.2174/187152506777698344 16842205 (Pubitemid 44027709)
11. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-kappaB. Frede S, Stockmann C, Freitag P, Fandrey J, Biochem J 2006 396 517 527 10.1042/BJ20051839 16533170 (Pubitemid 44228166)
12. Activation of hypoxia-inducible factor 1 during macrophage differentiation. Oda T, Hirota K, Nishi K, Takabuchi S, Oda S, Yamada H, Arai T, Fukuda K, Kita T, Adachi T, Semenza GL, Nohara R, Am J Physiol Cell Physiol 2006 291 104 113 10.1152/ajpcell.00614.2005
13. The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis. Muz B, Khan MN, Kiriakidis S, Paleolog EM, Arthritis Res Ther 2009 11 201 209 10.1186/ar2568 19222864
14. An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, Plum SM, J Rheumatol 2008 35 2119 2128 10.3899/jrheum.080302 18792999
15. Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: an effect independent of an anti-angiogenic action. Issekutz AC, Sapru K, Int Immunopharmacol 2008 8 708 716 10.1016/j.intimp.2008.01.016 18387513
16. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Rice JW, Veal JM, Fadden RP, Barabasz AF, Partridge JM, Barta TE, Dubois LG, Huang KH, Mabbett SR, Silinski MA, Steed PM, Hall SE, Arthritis Rheum 2008 58 3765 3775 10.1002/art.24047 19035474
17. Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. Yuan G, Nanduri J, Bhasker CR, Semenza GL, Prabhakar NR, J Biol Chem 2005 280 4321 4328 10.1074/jbc.M407706200 15569687 (Pubitemid 40288600)
18. Calmodulin is a critical regulator of osteoclastic differentiation, function, and survival. Seales EC, Micoli KJ, McDonald JM, J Cell Biochem 2006 97 45 55 10.1002/jcb.20659 16216008 (Pubitemid 43050178)
19. CaMKII promotes TLR-triggered proinflammatory cytokine and type I interferon production by directly binding and activating TAK1 and IRF3 in macrophages. Liu X, Yao M, Li N, Wang C, Zheng Y, Cao X, Blood 2008 112 4961 4970 10.1182/blood-2008-03-144022 18818394
20. Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor. Westra J, Doornbos-Van Der Meer B, de Boer P, van Leeuwen MA, van Rijswijk MH, Limburg PC, Arthritis Res Ther 2004 6 384 R392 10.1186/ar1204 15225374
21. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW, Cancer Res 1999 59 5830 5835 10582706
22. Hypoxia inducible factor-1-alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis. Brouwer E, Gouw AS, Posthumus MD, van Leeuwen MA, Boerboom AL, Bijzet J, Bos R, Limburg PC, Kallenberg CG, Westra J, Clin Exp Rheumatol 2009 27 945 951 20149310
23. Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Giatromanolaki A, Sivridis E, Maltezos E, Athanassou N, Papazoglou D, Gatter KC, Harris AL, Koukourakis MI, Arthritis Res Ther 2003 5 193 R201 10.1186/ar756 12823854
24. The transcription factors hypoxia-inducible factor 1alpha and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Peters CL, Morris CJ, Mapp PI, Blake DR, Lewis CE, Winrow VR, Arthritis Rheum 2004 50 291 296 10.1002/art.11473 14730627 (Pubitemid 38084314)
25. Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Hollander AP, Corke KP, Freemont AJ, Lewis CE, Arthritis Rheum 2001 44 1540 1544 10.1002/1529-0131(200107)44:7<1540::AID-ART277>3.0.CO;2- 7 11465705 (Pubitemid 32642216)
26. Stable expression of HIF-1{alpha} in tubular epithelial cells promotes interstitial fibrosis. Kimura K, Iwano M, Higgins DF, Yamaguchi Y, Nakatani K, Harada K, Kubo A, Akai Y, Rankin EB, Neilson EG, Haase VH, Saito Y, Am J Physiol Renal Physiol 2008 295 1023 F1029 10.1152/ajprenal.90209.2008 18667485
27. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Shin DH, Kim JH, Jung YJ, Kim KE, Jeong JM, Chun YS, Park JW, Cancer Lett 2007 255 107 116 10.1016/j.canlet.2007.03.026 17502124 (Pubitemid 47212610)
28. Proteomic approach to studying the cytotoxicity of YC-1 on U937 leukemia cells and antileukemia activity in orthotopic model of leukemia mice. Chung JG, Yang JS, Huang LJ, Lee FY, Teng CM, Tsai SC, Lin KL, Wang SF, Kuo SC, Proteomics 2007 7 3305 3317 10.1002/pmic.200700200 17849408 (Pubitemid 47517946)
29. Regulation of expression of matrix metalloproteinase-9 by JNK in Raw 264.7 cells: presence of inhibitory factor(s) suppressing MMP-9 induction in serum and conditioned media. Lee YS, Lan Tran HT, Van Ta TQ, Exp Mol Med 2009 41 259 268 10.3858/emm.2009.41.4.029 19299915
30. Hypoxia modulates lipopolysaccharide induced TNF-alpha expression in murine macrophages. Liu FQ, Liu Y, Lui VC, Lamb JR, Tam PK, Chen Y, Exp Cell Res 2008 314 1327 1336 10.1016/j.yexcr.2008.01.007 18255061
31. Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. Fang HY, Hughes R, Murdoch C, Coffelt SB, Biswas SK, Harris AL, Johnson RS, Imityaz HZ, Simon MC, Fredlund E, Greten FR, Rius J, Lewis CE, Blood 2009 114 844 859 10.1182/blood-2008-12-195941 19454749
32. In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis. Haas CS, Amin MA, Ruth JH, Allen BL, Ahmed S, Pakozdi A, Woods JM, Shahrara S, Koch AE, Arthritis Rheum 2007 56 2535 2548 10.1002/art.22823 17665443 (Pubitemid 47237272)
33. Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study. Strunk J, Bundke E, Lange U, Rheumatol Int 2006 26 252 256 10.1007/s00296-005-0619-5 15999273 (Pubitemid 41830984)